Antimicrobial Agents Practice Questions

Q: A 60-year-old man is diagnosed with hospital-acquired bacterial endocarditis and empiric broad-spectrum coverage is needed. Which beta-lactamase inhibitor combined with an anti-pseudomonal penicillin provides the broadest coverage in this context?

Tazobactam. ***Tazobactam*** - **Tazobactam** combined with **piperacillin** (piperacillin-tazobactam) provides the **broadest spectrum coverage** among beta-lactamase inhibitor combinations, particularly for hospital-acquired infections. - It is effective against a wide range of bacteria including **ESBL-producing organisms**, Pseudomonas aeruginosa, and many Gram-positive and Gram-negative bacteria. - In the context of **hospital-acquired endocarditis** where broad empiric coverage is needed, piperacillin-tazobactam is frequently chosen due to its **enhanced activity against resistant organisms** and coverage of nosocomial pathogens. *Sulbactam* - **Sulbactam** is combined with ampicillin and is effective against **beta-lactamase-producing Staphylococcus aureus** and certain Gram-negative bacteria. - While useful in some endocarditis cases (particularly community-acquired), it has a **narrower spectrum** compared to tazobactam and lacks reliable anti-pseudomonal activity. *Clavulanic acid* - **Clavulanic acid** is combined with amoxicillin or ticarcillin and covers **Gram-positive and some Gram-negative bacteria**. - Its spectrum of beta-lactamase inhibition is **more limited** than tazobactam, particularly against ESBL-producing organisms common in hospital settings. - Amoxicillin-clavulanate is rarely used for endocarditis treatment. *All of the options* - While all three are beta-lactamase inhibitors used in various infections, **tazobactam** (in combination with piperacillin) provides the **broadest spectrum** and is most appropriate for empiric therapy in hospital-acquired endocarditis requiring coverage of resistant organisms. - The choice depends on **suspected pathogen**, local resistance patterns, and infection severity, but for broad empiric coverage in nosocomial infections, piperacillin-tazobactam is preferred.

Q: Which drug was among the first antivirals to receive emergency authorization for COVID-19 treatment and works by inhibiting viral RNA polymerase?

Remdesivir. ***Remdesivir*** - **Remdesivir** is an **adenosine nucleotide analog** that inhibits viral **RNA-dependent RNA polymerase (RdRp)**, thereby disrupting **viral replication**. - It was **one of the first antiviral drugs** to receive emergency use authorization for treating COVID-19, particularly in **hospitalized patients with severe disease**. - Administered **intravenously**, it directly targets the viral replication machinery. *Paxlovid (nirmatrelvir-ritonavir)* - While highly effective in reducing viral replication, **Paxlovid** is a **protease inhibitor combination** with a different mechanism of action. - **Nirmatrelvir** targets the **SARS-CoV-2 main protease (Mpro)**, not RNA polymerase, preventing the virus from processing polyproteins necessary for replication. - It received authorization **later** than remdesivir and is given **orally** for outpatient use. *Molnupiravir* - **Molnupiravir** is an oral antiviral that induces **lethal mutations in viral RNA** (error catastrophe), a mechanism distinct from **RNA polymerase inhibition**. - While it reduces viral replication, it does not work by inhibiting viral RNA polymerase specifically. *Ibuprofen* - **Ibuprofen** is a **non-steroidal anti-inflammatory drug (NSAID)** used to manage **fever, pain, and inflammation** associated with COVID-19. - It has **no direct antiviral activity** and does not inhibit viral replication—it provides purely **symptomatic relief**.

Q: A patient with tuberculosis is given a first-line treatment regimen that includes a drug that inhibits mycolic acid synthesis. Which drug is appropriate?

Isoniazid. ***Isoniazid*** - **Isoniazid** is a prodrug that, once activated by the bacterial catalase-peroxidase enzyme **KatG**, inhibits **mycolic acid synthesis**. - Its mechanism involves interfering with the synthesis of **mycolic acids**, which are essential components of the **mycobacterial cell wall**, leading to its bactericidal effect. *Rifampin* - **Rifampin** inhibits **bacterial DNA-dependent RNA polymerase (DDRP)**, thereby blocking RNA synthesis. - This drug is known for its ability to penetrate macrophages and act on bacteria within these cells, and it contributes to the sterilizing activity of TB regimens. *Pyrazinamide* - **Pyrazinamide** is a prodrug converted to pyrazinoic acid in acidic environments, which disrupts **mycobacterial metabolism** and membrane function. - Its exact mechanism is not fully understood, but it is known to be effective against **intracellular M. tuberculosis** in acidic phagosomal environments. *Ethambutol* - **Ethambutol** inhibits **arabinosyl transferase**, an enzyme involved in the synthesis of the **arabinogalactan component of the mycobacterial cell wall**. - This inhibition prevents the formation of the complex mycobacterial cell wall, making the bacteria more susceptible to other anti-TB drugs.

Q: A patient with severe COVID-19 is treated with an adenosine nucleoside analog antiviral drug that inhibits RNA-dependent RNA polymerase. Which drug is this likely to be?

Remdesivir. ***Remdesivir*** - **Remdesivir** is an **adenosine nucleoside analog** that acts as a **prodrug** and is metabolized intracellularly to its active triphosphate form. - This active form then inhibits **viral RNA-dependent RNA polymerase (RdRp)**, thereby disrupting viral replication in severe **COVID-19**. - It has been the primary established antiviral with WHO recommendation for hospitalized patients with severe COVID-19. *Favipiravir* - **Favipiravir** is a **purine (guanine) analog** antiviral that also targets **RdRp** in RNA viruses. - While it has been explored for COVID-19 in some countries, it is chemically distinct (purine vs. adenosine analog) and lacks the same level of established efficacy evidence for severe COVID-19. - Its primary established use is for **influenza** in some regions (Japan). *Ribavirin* - **Ribavirin** is a guanosine analog with broad-spectrum antiviral activity, often used in combination therapy for **chronic hepatitis C**. - Its mechanism involves interfering with **RNA synthesis** and processing, but it is not a primary treatment for COVID-19. *Oseltamivir* - **Oseltamivir** is a **neuraminidase inhibitor** used to treat and prevent **influenza A and B**. - It works by preventing the release of new viral particles from infected cells, a mechanism distinct from **RdRp inhibition** and unrelated to COVID-19 treatment.

Q: Which macrolide drug is used as a penicillin substitute for patients who are allergic and is known to inhibit protein synthesis?

Azithromycin. ***Azithromycin*** - Azithromycin is a **macrolide antibiotic** that inhibits **bacterial protein synthesis** by binding to the **50S ribosomal subunit**. - It is frequently used as an alternative for patients with a **penicillin allergy**, especially for respiratory tract infections and some sexually transmitted infections. *Vancomycin* - Vancomycin is a **glycopeptide antibiotic** that inhibits **cell wall synthesis** by interfering with peptidoglycan formation, not protein synthesis. - It is primarily used for **MRSA infections** and *Clostridioides difficile* colitis, and is not a common penicillin substitute for general infections. *Clindamycin* - Clindamycin is a **lincosamide antibiotic** that inhibits **protein synthesis** by binding to the **50S ribosomal subunit**, similar to macrolides. - While it can be used in penicillin-allergic patients, its spectrum is more focused on **anaerobic bacteria** and some gram-positive cocci, and it is more associated with *Clostridioides difficile* infection. *Ciprofloxacin* - Ciprofloxacin is a **fluoroquinolone antibiotic** that inhibits bacterial **DNA gyrase** and **topoisomerase IV**, thereby blocking DNA replication. - It does not inhibit protein synthesis and is not typically considered a first-line penicillin substitute for common infections due to its broader spectrum and potential side effects.

Q: A 45-year-old farmer presents with chronic cough and weight loss. Sputum microscopy reveals branching septate hyphae. Which antifungal agent should be initiated while awaiting the culture results?

Voriconazole. ***Voriconazole*** - The description of **branching septate hyphae** in a patient with chronic cough and weight loss is highly suggestive of **aspergillosis**. - **Voriconazole** is the **preferred first-line treatment** for invasive aspergillosis due to its superior efficacy, better tolerability, and convenience of administration compared to other antifungals. - It has excellent activity against *Aspergillus* species and achieves good tissue penetration. *Amphotericin B* - **Liposomal Amphotericin B** is an **alternative first-line agent** for invasive aspergillosis, particularly when voriconazole is contraindicated or unavailable. - However, it requires **intravenous administration**, has a higher incidence of **serious side effects** including nephrotoxicity and infusion-related reactions, making voriconazole the preferred initial choice when both are available. *Fluconazole* - **Fluconazole** is primarily active against *Candida* species and *Cryptococcus neoformans*. - It has **poor or no activity** against *Aspergillus* species and is therefore not an appropriate choice for suspected aspergillosis. *Itraconazole* - **Itraconazole** has activity against *Aspergillus* and can be used as an alternative or step-down therapy for chronic pulmonary aspergillosis. - However, it is **less effective** than voriconazole for invasive disease, and its **variable oral absorption** and numerous drug interactions make it less ideal for empiric therapy in acute presentations.

Q: Which class of antibiotics is typically prescribed as the first-line therapy for community-acquired pneumonia?

Beta-lactams. ***Beta-lactams*** - **Beta-lactam antibiotics**, such as **amoxicillin** or **ceftriaxone**, are commonly recommended as first-line agents for **community-acquired pneumonia (CAP)**, especially in patients without recent antibiotic use or significant comorbidities. - They effectively target common bacterial pathogens like *Streptococcus pneumoniae* which are frequent causes of CAP. *Aminoglycosides* - **Aminoglycosides** are typically reserved for severe infections, particularly those caused by **gram-negative bacteria**, and are not first-line for uncomplicated CAP due to their potential for **nephrotoxicity** and **ototoxicity**. - They also have **poor activity** against atypical pathogens and *Streptococcus pneumoniae*. *Tetracyclines* - **Tetracyclines**, particularly **doxycycline**, can be used as an alternative or in combination for CAP, especially when **atypical pathogens** like *Mycoplasma pneumoniae* or *Chlamydophila pneumoniae* are suspected. - However, they are not universally recommended as the sole first-line agent, especially in areas with high rates of resistance. *Fluoroquinolones* - **Respiratory fluoroquinolones** (e.g., **levofloxacin**, **moxifloxacin**) are highly effective against CAP pathogens, including atypical bacteria and drug-resistant *Streptococcus pneumoniae*. - They are often reserved for patients with comorbidities, recent antibiotic use, or those requiring hospitalization, to help **prevent resistance development** when other agents are sufficient.

Q: Which antifungal drug inhibits ergosterol synthesis and is widely used for systemic fungal infections including candidiasis and cryptococcosis?

Fluconazole. ***Fluconazole*** - Fluconazole is an **azole antifungal** that inhibits **14-alpha-demethylase**, an enzyme crucial for **ergosterol synthesis** in fungal cell membranes, thereby disrupting membrane integrity. - It is effective against a wide range of **systemic fungal infections**, particularly candidiasis, and is known for good oral bioavailability and penetration into the central nervous system. *Terbinafine* - Terbinafine is an **allylamine antifungal** that inhibits **squalene epoxidase**, an early step in ergosterol synthesis, leading to accumulation of toxic squalene. - It is primarily used for **dermatophyte infections** (e.g., onychomycosis) and less commonly for systemic fungal infections. *Amphotericin B* - Amphotericin B is a **polyene antifungal** that directly binds to **ergosterol** in the fungal cell membrane, forming pores and causing leakage of intracellular contents. - It is a **broad-spectrum antifungal** often considered a "last resort" for severe, life-threatening systemic fungal infections due to its significant toxicity. *Caspofungin* - Caspofungin is an **echinocandin antifungal** that inhibits **beta (1,3)-D-glucan synthase**, an enzyme essential for the synthesis of **glucan** in the fungal cell wall, leading to cell wall instability and lysis. - It is effective against *Candida* species and *Aspergillus* but does not target ergosterol synthesis.

Q: Which antiviral drug is most effective in treating hepatitis C due to its direct-acting antiviral mechanism?

Sofosbuvir. ***Sofosbuvir*** - **Sofosbuvir** is a **nucleotide analog inhibitor** that targets the **HCV NS5B RNA polymerase**, a crucial enzyme for viral replication. - It is a cornerstone of **direct-acting antiviral (DAA) regimens** for hepatitis C, achieving high cure rates across various genotypes [1]. *Oseltamivir* - **Oseltamivir** is an **antiviral drug** primarily used to treat and prevent **influenza A and B viruses** by inhibiting neuraminidase. - It has **no activity** against the **hepatitis C virus (HCV)**. *Lamivudine* - **Lamivudine** is a **nucleoside analog reverse transcriptase inhibitor** primarily used to treat **HIV infection** and **chronic hepatitis B virus (HBV) infection** [2]. - While it's an antiviral, it is **not effective** against the **hepatitis C virus (HCV)**. *Acyclovir* - **Acyclovir** is an **antiviral agent** specifically active against **herpes simplex viruses (HSV)** and **varicella-zoster virus (VZV)** by inhibiting viral DNA polymerase. - It has **no therapeutic role** in the treatment of **hepatitis C virus (HCV)** infection.

Q: A patient with a severe penicillin allergy requires treatment for syphilis. Which alternative antibiotic should be considered?

Doxycycline. ***Doxycycline*** - **Doxycycline** is the recommended alternative for treating **syphilis** in patients with a **severe penicillin allergy**. - It is an effective **tetracycline antibiotic** that inhibits protein synthesis in *Treponema pallidum*. - Preferred over cephalosporins in severe allergies due to **no cross-reactivity** with penicillin. *Amoxicillin* - **Amoxicillin** is a **penicillin-class antibiotic** and would be contraindicated in a patient with a severe penicillin allergy due to the risk of allergic reaction. - It works by inhibiting bacterial cell wall synthesis, similar to penicillin. *Ceftriaxone* - **Ceftriaxone** is a **third-generation cephalosporin**, which has a low but present risk of **cross-reactivity** (approximately 1-3%) with penicillin in patients with severe penicillin allergies. - While sometimes used as an alternative in **non-severe** allergies, **doxycycline** is preferred in cases of **severe allergy** due to its lack of cross-reactivity. *Vancomycin* - **Vancomycin** is an antibiotic primarily used for **Gram-positive bacterial infections**, particularly **MRSA**, and is not effective against *Treponema pallidum*. - It works by inhibiting cell wall synthesis, but its spectrum of activity does not cover syphilis effectively.

Question 1

A 60-year-old man is diagnosed with hospital-acquired bacterial endocarditis and empiric broad-spectrum coverage is needed. Which beta-lactamase inhibitor combined with an anti-pseudomonal penicillin provides the broadest coverage in this context?

Accepted Answer

Tazobactam

Answer

Sulbactam

Answer

Clavulanic acid

Answer

All of the options

Question 2

Which drug was among the first antivirals to receive emergency authorization for COVID-19 treatment and works by inhibiting viral RNA polymerase?

Accepted Answer

Remdesivir

Answer

Paxlovid (nirmatrelvir-ritonavir)

Answer

Ibuprofen

Answer

Molnupiravir

Question 3

A patient with tuberculosis is given a first-line treatment regimen that includes a drug that inhibits mycolic acid synthesis. Which drug is appropriate?

Accepted Answer

Isoniazid

Answer

Rifampin

Answer

Pyrazinamide

Answer

Ethambutol

Question 4

A patient with severe COVID-19 is treated with an adenosine nucleoside analog antiviral drug that inhibits RNA-dependent RNA polymerase. Which drug is this likely to be?

Accepted Answer

Remdesivir

Answer

Favipiravir

Answer

Ribavirin

Answer

Oseltamivir

Question 5

Which macrolide drug is used as a penicillin substitute for patients who are allergic and is known to inhibit protein synthesis?

Accepted Answer

Azithromycin

Answer

Vancomycin

Answer

Ciprofloxacin

Answer

Clindamycin

Question 6

A 45-year-old farmer presents with chronic cough and weight loss. Sputum microscopy reveals branching septate hyphae. Which antifungal agent should be initiated while awaiting the culture results?

Accepted Answer

Voriconazole

Answer

Amphotericin B

Answer

Fluconazole

Answer

Itraconazole

Question 7

Which class of antibiotics is typically prescribed as the first-line therapy for community-acquired pneumonia?

Accepted Answer

Beta-lactams

Answer

Aminoglycosides

Answer

Tetracyclines

Answer

Fluoroquinolones

Question 8

Which antifungal drug inhibits ergosterol synthesis and is widely used for systemic fungal infections including candidiasis and cryptococcosis?

Accepted Answer

Fluconazole

Answer

Terbinafine

Answer

Amphotericin B

Answer

Caspofungin

Question 9

Which antiviral drug is most effective in treating hepatitis C due to its direct-acting antiviral mechanism?

Accepted Answer

Sofosbuvir

Answer

Oseltamivir

Answer

Lamivudine

Answer

Acyclovir

Question 10

A patient with a severe penicillin allergy requires treatment for syphilis. Which alternative antibiotic should be considered?

Accepted Answer

Doxycycline

Answer

Amoxicillin

Answer

Ceftriaxone

Answer

Vancomycin

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?